Leiden, The Netherlands, 25 May 2016, Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) announces announces that at its Annual General Meeting (AGM) of shareholders, held today, all proposals were approved.

In addition, the Board of Supervisory Directors (BOSD)announced that Paul Sekhri is succeeding Jaap Blaak, who is stepping down after eight years as Chairman of the BOSD. Mr. Blaak will continue to serve on the BOSD.

Mr Sekhri joined the BOSD at last years’ AGM. He has 30 years of operational experience in life sciences with in-depth knowledge of multinational pharmaceutical and biotechnology markets and products. Mr. Sekhri is currently President and Chief Executive Officer of Lycera Corp., a biopharmaceutical company developing breakthrough medicines to treat cancer and autoimmune disease. Prior to joining Lycera, Mr. Sekhri was Senior Vice President, Integrated Care at Sanofi, where he led the creation of innovative solutions and business models to meet patient needs. Previously, he has served as Group Executive Vice President, Global Business Development and Chief Strategy Officer at Teva Pharmaceutical Industries Ltd. Mr. Sekhri has held positions in small biopharmaceutical companies, large and small pharmaceutical companies, and venture capital/private equity firms, including, Cerimon Pharmaceuticals, Novartis AG, Ariad Pharmaceuticals and TPG Biotech. Mr. Sekhri completed postgraduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine and received his BSc degree from the University of Maryland. In addition to his board position with Lycera, he currently serves on other public and private boards including Enumeral Holdings, Inc., Nivalis Therapeutics, Inc., and Veeva Systems, Inc. as well as several non-profit boards including Caramoor Music and Arts Center, Young Concert Artists, Inc., the TB Alliance and the Cancer Research Institute, and he is a member of the Patrons Council of Carnegie Hall where he served as a member of the Board of Trustees from 2010-2012.

Sijmen de Vries, Pharming’s CEO commented; “We are delighted that Paul has agreed to become Chairman of the BOSD at this exciting time in Pharming’s development. His extensive industry experience and network will be important assets to support the growth trajectory ahead of us. Jaap has been Chairman of the BOSD and has performed an excellent job, during a very difficult time for Pharming, and all of us at the Company feel grateful for his wisdom, support, tenacity and leadership during his tenure as Chairman over the last eight years; an exciting period, one with many serious challenges that have been overcome.”

The presentation slides from today’s AGM are available on the Company’s website

tijd 09.17
Pharming EUR 0,199 -0,001ct vol. 466.073